Insider-Transaktionen

EDGAR

Evoke Pharma Inc

Von Direktoren, Führungskräften und 10-%-Eignern auf den SEC-Formularen 3, 4 und 5 gemeldete Transaktionen, aus dem XML jeder Einreichung gelesen. Codes und ihr Wortlaut stammen von der SEC.

Das Formular 4 ist innerhalb von zwei Geschäftstagen nach der Transaktion einzureichen; die jüngsten Geschäfte sind daher möglicherweise noch nicht gemeldet.

Zeitfenster: Transaktionen ab dem 16. Nov. 2025.

Käufe am offenen Markt (Code P)
0 Transaktionen, — Aktien
Verkäufe am offenen Markt (Code S)
0 Transaktionen, — Aktien

Die Summen addieren die aufgeführten eingereichten Transaktionen; sie zählen das Gemeldete und messen keine Richtung.

1–37 von 37 angezeigt

Insider-Transaktionen, neueste zuerst, wie auf den SEC-Formularen 3, 4 und 5 eingereicht
DatumMeldende PersonCodeErworben oder veräußertAktienPreis je Aktie, wie eingereichtWert (abgeleitet)Aktien danach im BesitzDirekt oder indirektKästchen zu Rule 10b5-1AnmerkungenQuelle
17. Dez. 2025 Eingereicht am 19. Dez. 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
Veräußert (D)148.15311,00
1.629.683

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 1629683.00.

0Indirekt (I) See FootnoteNein
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Einreichung öffnen 0001104659-25-123156 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 19. Dez. 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Prefunded Warrants — Basiswert Common Stock (433.962) — Ausübungspreis 0.0001
Veräußert (D)433.96210,999
4.773.148,038

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 4773148.038.

0Indirekt (I) See FootnoteNein
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Einreichung öffnen 0001104659-25-123156 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 19. Dez. 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Series A Common Stock Purchase Warrants — Basiswert Common Stock (117.019) — Ausübungspreis 8.16
Veräußert (D)117.0194,71
551.159,49

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 551159.49.

0Indirekt (I) See FootnoteNein
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Einreichung öffnen 0001104659-25-123156 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 19. Dez. 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Series C Common Stock Purchase Warrants — Basiswert Common Stock (117.019) — Ausübungspreis 8.16
Veräußert (D)117.0194,71
551.159,49

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 551159.49.

0Indirekt (I) See FootnoteNein
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Einreichung öffnen 0001104659-25-123156 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 19. Dez. 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Amended Series A Common Stock Purchase Warrants — Basiswert Common Stock (158.531) — Ausübungspreis 0.01
Veräußert (D)158.53110,99
1.742.255,69

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 1742255.69.

0Indirekt (I) See FootnoteNein
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Einreichung öffnen 0001104659-25-123156 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 19. Dez. 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Derivatives Wertpapier: Amended Series C Common Stock Purchase Warrants — Basiswert Common Stock (250.627) — Ausübungspreis 0.01
Veräußert (D)250.62710,99
2.754.390,73

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 2754390.73.

0Indirekt (I) See FootnoteNein
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Einreichung öffnen 0001104659-25-123156 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (1.218) — Ausübungspreis 5.41
Veräußert (D)1.218——0Direkt (D) Nein
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322642 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (5.833) — Ausübungspreis 4.45
Veräußert (D)5.833——0Direkt (D) Nein
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322642 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (1.218) — Ausübungspreis 3.453
Veräußert (D)1.218——0Direkt (D) Nein
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322642 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (1.479) — Ausübungspreis 5.41
Veräußert (D)1.479——0Direkt (D) Nein
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322643 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (8.750) — Ausübungspreis 4.45
Veräußert (D)8.750——0Direkt (D) Nein
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322643 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (1.291) — Ausübungspreis 3.453
Veräußert (D)1.291——0Direkt (D) Nein
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322643 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (1.187) — Ausübungspreis 5.41
Veräußert (D)1.187——0Direkt (D) Nein
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322641 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (5.833) — Ausübungspreis 4.45
Veräußert (D)5.833——0Direkt (D) Nein
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322641 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (1.187) — Ausübungspreis 3.453
Veräußert (D)1.187——0Direkt (D) Nein
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322641 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (1.250) — Ausübungspreis 5.41
Veräußert (D)1.250——0Direkt (D) Nein
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322638 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (5.833) — Ausübungspreis 4.45
Veräußert (D)5.833——0Direkt (D) Nein
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322638 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (1.250) — Ausübungspreis 3.453
Veräußert (D)1.250——0Direkt (D) Nein
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322638 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (1.218) — Ausübungspreis 5.41
Veräußert (D)1.218——0Direkt (D) Nein
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322639 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (5.833) — Ausübungspreis 4.45
Veräußert (D)5.833——0Direkt (D) Nein
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322639 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (1.187) — Ausübungspreis 3.453
Veräußert (D)1.187——0Direkt (D) Nein
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322639 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (5.833) — Ausübungspreis 5.51
Veräußert (D)5.833——0Direkt (D) Nein
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322645 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (1.125) — Ausübungspreis 3.453
Veräußert (D)1.125——0Direkt (D) Nein
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322645 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (17.291) — Ausübungspreis 5.27
Veräußert (D)17.291——0Direkt (D) Nein
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322644 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (11.000) — Ausübungspreis 4.45
Veräußert (D)11.000——0Direkt (D) Nein
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322644 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (64.840) — Ausübungspreis 5.27
Veräußert (D)64.840——0Direkt (D) Nein
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322637 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (70.000) — Ausübungspreis 4.45
Veräußert (D)70.000——0Direkt (D) Nein
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322637 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (17.291) — Ausübungspreis 5.27
Veräußert (D)17.291——0Direkt (D) Nein
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322640 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (13.000) — Ausübungspreis 4.45
Veräußert (D)13.000——0Direkt (D) Nein
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322640 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (5.833) — Ausübungspreis 5.26
Veräußert (D)5.833——0Direkt (D) Nein
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322646 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
17. Dez. 2025 Eingereicht am 17. Dez. 2025PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (1.155) — Ausübungspreis 3.453
Veräußert (D)1.155——0Direkt (D) Nein
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Einreichung öffnen 0001193125-25-322646 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
16. Dez. 2025 Eingereicht am 17. Dez. 2025Hill Malcolm R Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Veräußert (D)133——0Direkt (D) Nein
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Einreichung öffnen 0001193125-25-322642 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
16. Dez. 2025 Eingereicht am 17. Dez. 2025GARNER CAM L Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Veräußert (D)2.330——0Indirekt (I) By Garner Investments, L.L.C.Nein
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Einreichung öffnen 0001193125-25-322643 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
16. Dez. 2025 Eingereicht am 17. Dez. 2025Brady Todd C Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Veräußert (D)27——0Direkt (D) Nein
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Einreichung öffnen 0001193125-25-322639 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
16. Dez. 2025 Eingereicht am 17. Dez. 2025CARLSON MARILYN R. Officer: Chief Medical Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Veräußert (D)360——0Direkt (D) Nein
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Einreichung öffnen 0001193125-25-322644 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
16. Dez. 2025 Eingereicht am 17. Dez. 2025D'Onofrio Matthew J Director · Officer: Chief Executive Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Veräußert (D)15.509——0Direkt (D) Nein
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Einreichung öffnen 0001193125-25-322637 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
16. Dez. 2025 Eingereicht am 17. Dez. 2025Kowieski Mark Officer: Chief Financial Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Veräußert (D)11.815——0Direkt (D) Nein
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Einreichung öffnen 0001193125-25-322640 Aus dem XML der Einreichung gelesen Diese Zeile anfechten

Institutionelle Halter (Formular 13F)

Im Speicher ist dieser Emittent keiner Form-13F-Position zugeordnet. Ein noch nicht verknüpfter oder noch nicht meldender Halter fehlt, er steht nicht bei null.

5-%-Halter (Schedule 13D und 13G)

Hier werden im strukturierten SEC-Format (ab Ende 2024) eingereichte Schedules gelesen. Frühere sind Freitext und werden nicht gelesen.

5-%-Halter, jüngstes Ereignis zuerst, wie eingereicht
HalterProzent der GattungGehaltene AktienEreignisdatumFormularQuelle
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share00,0012/17/2025 Eingereicht am 19. Dez. 2025SCHEDULE 13D/AÄnderung 5Einreichung öffnen 0001104659-25-123157 Diese Zeile anfechten
Harkey Wilmot B. Common Stock, par value $0.0001 per share00,0012/17/2025 Eingereicht am 19. Dez. 2025SCHEDULE 13D/AÄnderung 5Einreichung öffnen 0001104659-25-123157 Diese Zeile anfechten
Mack Daniel Common Stock, par value $0.0001 per share00,0012/17/2025 Eingereicht am 19. Dez. 2025SCHEDULE 13D/AÄnderung 5Einreichung öffnen 0001104659-25-123157 Diese Zeile anfechten
Morgan Stanley Common Stock0.03111/30/2025 Eingereicht am 5. Dez. 2025SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0000895421-25-000595 Diese Zeile anfechten
Morgan Stanley Smith Barney LLC Common Stock0.03111/30/2025 Eingereicht am 5. Dez. 2025SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0000895421-25-000595 Diese Zeile anfechten
Klein Roger M. Common Stock, par value $0.0001 per share10.5163.000,0011/04/2025 Eingereicht am 12. Nov. 2025SCHEDULE 13DEinreichung öffnen 0001651175-25-000007 Diese Zeile anfechten
Krieger Charitable Trust Common Stock, par value $0.0001 per share8.3129.000,0011/04/2025 Eingereicht am 12. Nov. 2025SCHEDULE 13DEinreichung öffnen 0001651175-25-000007 Diese Zeile anfechten
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share15.99268.431,0011/03/2025 Eingereicht am 4. Nov. 2025SCHEDULE 13D/AÄnderung 4Einreichung öffnen 0001104659-25-106048 Diese Zeile anfechten
Harkey Wilmot B. Common Stock, par value $0.0001 per share15.99268.431,0011/03/2025 Eingereicht am 4. Nov. 2025SCHEDULE 13D/AÄnderung 4Einreichung öffnen 0001104659-25-106048 Diese Zeile anfechten
Mack Daniel Common Stock, par value $0.0001 per share15.99268.431,0011/03/2025 Eingereicht am 4. Nov. 2025SCHEDULE 13D/AÄnderung 4Einreichung öffnen 0001104659-25-106048 Diese Zeile anfechten
Morgan Stanley Common Stock10.5163.71808/31/2025 Eingereicht am 8. Sept. 2025SCHEDULE 13GEinreichung öffnen 0000895421-25-000528 Diese Zeile anfechten
Morgan Stanley Smith Barney LLC Common Stock10.5163.71808/31/2025 Eingereicht am 8. Sept. 2025SCHEDULE 13GEinreichung öffnen 0000895421-25-000528 Diese Zeile anfechten

Der Prozentsatz bezieht sich auf die in der Einreichung genannte Gattung, wie vom Halter angegeben. Gruppenmitglieder melden jeweils die Aktien der Gruppe; die Zeilen werden daher nicht addiert.

Was gelesen wurde

2.092.408 Einreichungen gelesen, vom 14. Juni 2004 bis 13. Nov. 2026: Formulare 3, 3/A, 4, 4/A, 5, 5/A.

Jahre können unvollständig sein, solange das Archiv noch gelesen wird. Ein Jahr mit wenigen Einreichungen hier besagt nicht, dass wenige gemacht wurden.

Gelesene Einreichungen nach Einreichungsjahr
EinreichungsjahrGelesene Einreichungen
20151
2016204.322
2017202.494
2018202.048
2019193.638
2020144.184
2021224.474
202240.015
2023199.811
2024185.386
2025235.520
2026254.737

Einreichungen aus der Zeit vor der XML-Pflicht der SEC sind aufgeführt, aber nicht ausgelesen.

Zurück zu Evoke Pharma Inc